Wellington Management Group LLP Buys 521,272 Shares of Twist Bioscience Co. (NASDAQ:TWST)

Wellington Management Group LLP grew its position in shares of Twist Bioscience Co. (NASDAQ:TWST - Free Report) by 188.5% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 797,737 shares of the company's stock after acquiring an additional 521,272 shares during the quarter. Wellington Management Group LLP owned 1.36% of Twist Bioscience worth $36,042,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. Signaturefd LLC grew its holdings in Twist Bioscience by 63.0% in the 3rd quarter. Signaturefd LLC now owns 792 shares of the company's stock valued at $36,000 after buying an additional 306 shares in the last quarter. EdgeRock Capital LLC bought a new position in Twist Bioscience in the second quarter valued at about $43,000. Blue Trust Inc. raised its position in Twist Bioscience by 2,912.8% in the second quarter. Blue Trust Inc. now owns 1,175 shares of the company's stock valued at $58,000 after purchasing an additional 1,136 shares during the last quarter. DekaBank Deutsche Girozentrale bought a new position in Twist Bioscience in the second quarter valued at about $61,000. Finally, Mirae Asset Global Investments Co. Ltd. raised its position in shares of Twist Bioscience by 21.9% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,119 shares of the company's stock worth $98,000 after acquiring an additional 381 shares during the last quarter.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the company. Robert W. Baird raised their price objective on Twist Bioscience from $46.00 to $48.00 and gave the company an "outperform" rating in a research note on Tuesday, November 19th. Evercore ISI lifted their price target on Twist Bioscience from $52.00 to $56.00 and gave the stock an "outperform" rating in a report on Tuesday, October 1st. Wolfe Research initiated coverage on Twist Bioscience in a research note on Friday. They issued an "outperform" rating and a $60.00 target price on the stock. TD Cowen restated a "buy" rating and issued a $58.00 target price on shares of Twist Bioscience in a research note on Tuesday, November 26th. Finally, Leerink Partners boosted their price objective on Twist Bioscience from $45.00 to $48.00 and gave the company a "market perform" rating in a research note on Thursday, October 17th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $51.90.

Twist Bioscience Trading Down 0.8 %

Shares of TWST stock traded down $0.38 during trading hours on Friday, hitting $47.01. The company's stock had a trading volume of 251,152 shares, compared to its average volume of 938,428. The stock has a market cap of $2.79 billion, a price-to-earnings ratio of -13.16 and a beta of 1.82. The business has a fifty day moving average of $44.85 and a 200-day moving average of $46.60. Twist Bioscience Co. has a twelve month low of $27.41 and a twelve month high of $60.90.

Insiders Place Their Bets

In other news, SVP Paula Green sold 860 shares of the business's stock in a transaction that occurred on Friday, December 6th. The shares were sold at an average price of $52.70, for a total transaction of $45,322.00. Following the sale, the senior vice president now owns 133,715 shares in the company, valued at $7,046,780.50. The trade was a 0.64 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Dennis Cho sold 3,104 shares of the company's stock in a transaction that occurred on Wednesday, October 2nd. The shares were sold at an average price of $43.21, for a total transaction of $134,123.84. Following the completion of the transaction, the insider now owns 75,289 shares in the company, valued at approximately $3,253,237.69. This represents a 3.96 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 101,787 shares of company stock valued at $4,584,508 over the last quarter. Company insiders own 3.92% of the company's stock.

Twist Bioscience Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.